Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Combination of antigens from multiple viral species
Reexamination Certificate
2009-03-04
2011-12-13
Mosher, Mary E (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Combination of antigens from multiple viral species
C424S218100, C424S199100, C424S205100, C435S320100, C435S235100, C435S236000
Reexamination Certificate
active
08075903
ABSTRACT:
The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (Δ30) in the 3′-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.
REFERENCES:
patent: 7517531 (2009-04-01), Whitehead et al.
patent: 01/91790 (2001-12-01), None
patent: 02/095075 (2002-11-01), None
J.M. Troyer et al., “A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccine to mosquitoes”, Am. J. Trop, Med Hyg., vol. 65, pp. 414-419 (2001).
S.S. Whitehead et al., “A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3′ untranslated region is highly attenuated and immunogenic in monkeys”, J. Virol., vol. 77, pp. 1653-1657 (2003).
S.S. Whitehead et al., “Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys”, Vaccine, vol. 21, pp. 4307-4316 (2003).
M. Worobey et al., “Widespread intra-serotype recombination in natural populations of dengue virus”, PNAS USA, vol. 96, pp. 7352-7357 (1999).
L. Zeng et al., “Identification of specific nucleotide sequences within the conserved 3′-SL in the dengue type 2 virus genome required for replication”, J. Virol., vol. 72, pp. 7510-7522 (1998).
N. Bhamarapravati et al., “Live attenuated tetravalent dengue vaccine”, Vaccine, vol. 18, pp. 44-47 (2000).
J.E. Blaney, Jr. et al., “Development of a Live Attenuated Dengue Virus Vaccine Using Reverse Genetics”, Viral Immunol., vol. 19, pp. 10-32 (2006).
A.P. Durbin et al., “The Recombinant Live Attenuated Dengue 4 Candidate Vaccine rDEN4delta30 is Safe, Immunogenic, and Highly Infectious in Healthy Adults”, Am. J. Trop. Med. Hyg., p. 361, Abstract 379 (2003).
K.A. Hanley et al., “Paired Charge-to-Alanine Mutagenesis of Dengue Virus Type 4 NS5 Generates Mutants with Temperature-Sensitive, Host Range, and Mouse Attenuation Phenotypes”, J. Virol., vol. 76, pp. 525-531 (2002).
N. Kanesa-Thasan et al., “Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers”, Vaccine, vol. 19, pp. 3179-3188 (2001).
Durbin et al., Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3′-untranslated region, American Journal of Tropical Medicine and Hygeine, vol. 65, pp. 405-413 (2001).
Lai et al., Clinical and Diagnostic Virology, vol. 10, pp. 173-179 (1998).
Olsthoorn et al., RNA, vol. 7, pp. 1370-1377 (2001).
Blaney et al., Journal of Virology, vol. 79, pp. 5516-5528 (2005).
Proutski et al., Virus Research, vol. 64, pp. 107-123 (1999).
J. An et al., “Development of a novel mouse model for dengue virus infection”, Virology, vol. 263, pp. 70-77 (1999).
A.D.T. Barrett et al., “Yellow fever vaccines”, Biologicals, vol. 25, pp. 17-25 (1997).
J.L. Blackwell et al., “Translation elongation factor-1 alpha interacts with the 3′ stem-loop region of West Nile virus genomic RNA”, J. Virol., vol. 71, pp. 6433-6444 (1997).
J.E. Blaney, Jr., et al., “Chemical mutagenesis of dengue virus type 4 yields mutant viruses which are temperature sensitive in vero cells or human liver cells and attenuated in mice”, J. Virol., vol. 75, pp. 9731-9740 (2001).
J.E. Blaney, Jr., et al., “Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells”, Virology, vol. 300, pp. 125-139 (2002).
J.E. Blaney, Jr. et al. “Mutations which enhance the replication of dengue virus type 4 and an antigenic chimeric dengue virus type 2/4 vaccine candidate in Vero cells”, Vaccine, vol. 21, pp. 4317-4327 (2003).
J.E. Blaney, Jr., et al., “Genetically modified, live attenuated dengue virus type 3 vaccine candidates”, Am. J. Trop. Med. Hyg., vol. 71, pp. 811-821 (2004).
J.E. Blaney, Jr. et al. “Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2”, BMC Infect. Dis., 4(39), 10 pages (2004).
J. Blok et al, “Comparison of a dengue-2 virus and its candidate vaccine derivative: sequence relationships with the flaviviruses and other viruses”, Virology, vol. 187, pp. 573-590 (1992).
M. Bray et al., “Construction of intertypic chimeric dengue viruses by substitution of structural protein genes”, PNAS USA, vol. 88, pp. 10342-10346 (1991).
M. Bray et al., “Monkeys immunized with intertypic chimeric dengue viruses are protected against wild-type virus challenge”, J. Virol., vol. 70, pp. 4162-4166 (1996).
M. Bray et al., “Genetic determinants responsible for acquisition of dengue type 2 virus mouse neurovirulence”, J. Virol., vol. 72, pp. 1647-1651 (1998).
M.A. Brinton et al., “The 3′-nucleotides of flavivirus genomic RNA form a conserved secondary structure”, Virology, vol. 153, pp. 113-121 (1986).
D.S. Burke et al., “A prospective study of dengue infections in Bangkok”, Am. J. Trop. Med. Hyg., vol. 38, pp. 172-180 (1988).
S. Butrapet et al., “Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5′ noncoding region and nonstructural proteins 1 and 3”, J. Virol., vol. 74, pp. 3011-3019 (2000).
T.J. Chambers et al., “Yellow fever virus/dengue-2 virus and yellow fever virus/dengue-4 virus chimeras: biological characterization, immunogenicity, and protection against dengue encephalitis in the mouse model”, J. Virol., vol. 77, pp. 3655-3668 (2003).
W. Chen et al., “Construction of intertypic chimeric dengue viruses exhibiting type 3 antigenicity and neurovirulence for mice”, J. Virol., vol. 69, pp. 5186-5190 (1995).
D.J. Gubler et al., “Impact of dengue/dengue hemorrhagic fever on the developing world”, Adv. Virus Res., vol. 53, pp. 35-70 (1999).
S. Guillot et al., “Natural genetic exchanges between vaccine and wild poliovirus strains in humans”, J. Virol., vol. 74, pp. 8434-8443 (2000).
F. Guirakhoo et al., “Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine”, J. Virol., vol. 75, pp. 7290-7304 (2001).
F. Guirakhoo et al., “Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates”, Virology, vol. 298, pp. 146-159 (2002).
C.S. Hahn et al., “Conserved elements in the 3′ untranslated region of flavivirus RNAs and potential cyclization sequences”, J. Mol. Biol., vol. 198, pp. 33-41 (1987).
K.A. Hanley et al., “Introduction of mutations into the non-structural genes or 3′ untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity”, Vaccine, vol. 22, pp. 3440-3448 (2004).
C.Y. Huang et al., “Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine”, J. Virol., vol. 74, pp. 3020-3028 (2000).
O. Kew et al., “Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus”, Science, vol. 296, pp. 356-359 (2002).
A.A. Khromykh et al., “RNA binding properties of core protein of the flavivirus Kunjin”, Arch. Virol., vol. 141, pp. 685-699 (1996).
C.J. Lai et al., “Infectious RNA transcribed from stably cloned full-lengt
Blaney Joseph
Falgout Barry
Hanley Kathryn
Markoff Lewis
Murphy Brian R.
Corless Peter F.
Edwards Wildman Palmer LLP
Mosher Mary E
The United States of America as represented by the Department of
LandOfFree
Dengue tetravalent vaccine containing a common 30 nucleotide... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dengue tetravalent vaccine containing a common 30 nucleotide..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dengue tetravalent vaccine containing a common 30 nucleotide... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4252795